{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T16:20:10Z","timestamp":1794327610121,"version":"4.9.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2023,9,30]],"date-time":"2023-09-30T00:00:00Z","timestamp":1696032000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,9,30]],"date-time":"2023-09-30T00:00:00Z","timestamp":1696032000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100010877","name":"ViiV Healthcare","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100010877","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1007\/s12325-023-02656-1","type":"journal-article","created":{"date-parts":[[2023,9,30]],"date-time":"2023-09-30T08:02:07Z","timestamp":1696060927000},"page":"5300-5314","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Psychometric Validation of the Perception of Injection (PIN) Questionnaire Using Data From Two Phase III, Open-Label, Active-Controlled, Non-Inferiority Studies in People Living With HIV"],"prefix":"10.1007","volume":"40","author":[{"given":"Vasiliki","family":"Chounta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hilary F.","family":"Byrnes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mickael","family":"Henry-Szatkowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominy","family":"Browning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Donatti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy","family":"Lambert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,9,30]]},"reference":[{"key":"2656_CR1","doi-asserted-by":"publisher","unstructured":"Arts EJ, Hazuda DJ. HIV-1 antiretroviral drug therapy. Cold Spring Harb Perspect Med. 2012;2:a007161. https:\/\/doi.org\/10.1101\/cshperspect.a007161.","DOI":"10.1101\/cshperspect.a007161"},{"key":"2656_CR2","first-page":"s231","volume":"19","author":"KL Schaecher","year":"2013","unstructured":"Schaecher KL. The importance of treatment adherence in HIV. Am J Manag Care. 2013;19:s231\u20137.","journal-title":"Am J Manag Care"},{"key":"2656_CR3","unstructured":"ViiV Healthcare. CABENUVA prescribing information. In: Drugs@FDA: FDA-Approved Drugs. US Food and Drug Administration (FDA). 2022. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/212888s002lbl.pdf. Accessed 24 Jan 2022."},{"key":"2656_CR4","doi-asserted-by":"publisher","first-page":"3473","DOI":"10.1007\/s10461-020-02918-x","volume":"24","author":"A Mantsios","year":"2020","unstructured":"Mantsios A, Murray M, Karver TS, Davis W, Margolis D, Kumar P, Swindells S, Bredeek UF, Garc\u00eda Del Toro M, Garcia Gasalla M, Rubio Garc\u00eda R, Antela A, Hudson K, Griffith S, Kerrigan D. Efficacy and freedom: patient experiences with the transition from daily oral to long-acting injectable antiretroviral therapy to treat hiv in the context of phase 3 trials. AIDS Behav. 2020;24:3473\u201381. https:\/\/doi.org\/10.1007\/s10461-020-02918-x.","journal-title":"AIDS Behav"},{"key":"2656_CR5","doi-asserted-by":"publisher","first-page":"831","DOI":"10.3389\/fphar.2017.00831","volume":"8","author":"SA Iacob","year":"2017","unstructured":"Iacob SA, Iacob DG, Jugulete G. Improving the adherence to antiretroviral therapy, a difficult but essential task for a successful HIV treatment-clinical points of view and practical considerations. Front Pharmacol. 2017;8:831. https:\/\/doi.org\/10.3389\/fphar.2017.00831.","journal-title":"Front Pharmacol"},{"key":"2656_CR6","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/1477-7525-7-21","volume":"7","author":"C Chevat","year":"2009","unstructured":"Chevat C, Viala-Danten M, Dias-Barbosa C, Nguyen VH. Development and psychometric validation of a self-administered questionnaire assessing the acceptance of influenza vaccination: the Vaccinees\u2019 Perception of Injection (VAPI) questionnaire. Health Qual Life Outcomes. 2009;7:21. https:\/\/doi.org\/10.1186\/1477-7525-7-21.","journal-title":"Health Qual Life Outcomes"},{"key":"2656_CR7","doi-asserted-by":"publisher","first-page":"3533","DOI":"10.1007\/s10461-020-02929-8","volume":"24","author":"M Murray","year":"2020","unstructured":"Murray M, Antela A, Mills A, Huang J, Jager H, Bernal E, Lombaard J, Katner H, Walmsley S, Khuong-Josses MA, Hudson K, Dorey D, Griffith S, Spreen W, Vanveggel S, Shaefer M, Margolis D, Chounta V. Patient-reported outcomes in ATLAS and FLAIR participants on long-acting regimens of cabotegravir and rilpivirine over 48\u00a0weeks. AIDS Behav. 2020;24:3533\u201344. https:\/\/doi.org\/10.1007\/s10461-020-02929-8.","journal-title":"AIDS Behav"},{"key":"2656_CR8","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1056\/NEJMoa1909512","volume":"382","author":"C Orkin","year":"2020","unstructured":"Orkin C, Arasteh K, Gorgolas Hernandez-Mora M, Pokrovsky V, Overton ET, Girard PM, Oka S, Walmsley S, Bettacchi C, Brinson C, Philibert P, Lombaard J, St Clair M, Crauwels H, Ford SL, Patel P, Chounta V, D\u2019Amico R, Vanveggel S, Dorey D, Cutrell A, Griffith S, Margolis DA, Williams PE, Parys W, Smith KY, Spreen WR. Long-acting cabotegravir and rilpivirine after oral induction for HIV-1 infection. N Engl J Med. 2020;382:1124\u201335. https:\/\/doi.org\/10.1056\/NEJMoa1909512.","journal-title":"N Engl J Med"},{"key":"2656_CR9","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1056\/NEJMoa1904398","volume":"382","author":"S Swindells","year":"2020","unstructured":"Swindells S, Andrade-Villanueva JF, Richmond GJ, Rizzardini G, Baumgarten A, Masia M, Latiff G, Pokrovsky V, Bredeek F, Smith G, Cahn P, Kim YS, Ford SL, Talarico CL, Patel P, Chounta V, Crauwels H, Parys W, Vanveggel S, Mrus J, Huang J, Harrington CM, Hudson KJ, Margolis DA, Smith KY, Williams PE, Spreen WR. Long-acting cabotegravir and rilpivirine for maintenance of HIV-1 suppression. N Engl J Med. 2020;382:1112\u201323. https:\/\/doi.org\/10.1056\/NEJMoa1904398.","journal-title":"N Engl J Med"},{"key":"2656_CR10","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1097\/00005650-199603000-00003","volume":"34","author":"J Ware Jr","year":"1996","unstructured":"Ware J Jr, Kosinski M, Keller SD. A 12-Item Short-Form Health Survey: construction of scales and preliminary tests of reliability and validity. Med Care. 1996;34:220\u201333. https:\/\/doi.org\/10.1097\/00005650-199603000-00003.","journal-title":"Med Care"},{"key":"2656_CR11","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1097\/00005650-199802000-00004","volume":"36","author":"WC Holmes","year":"1998","unstructured":"Holmes WC, Shea JA. A new HIV\/AIDS-targeted quality of life (HAT-QoL) instrument: development, reliability, and validity. Med Care. 1998;36:138\u201354. https:\/\/doi.org\/10.1097\/00005650-199802000-00004.","journal-title":"Med Care"},{"key":"2656_CR12","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1111\/j.1524-4733.2006.00121.x","volume":"9","author":"A Woodcock","year":"2006","unstructured":"Woodcock A, Bradley C. Validation of the revised 10-item HIV Treatment Satisfaction Questionnaire status version and new change version. Value Health. 2006;9:320\u201333. https:\/\/doi.org\/10.1111\/j.1524-4733.2006.00121.x.","journal-title":"Value Health"},{"key":"2656_CR13","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1023\/A:1013050904635","volume":"10","author":"A Woodcock","year":"2001","unstructured":"Woodcock A, Bradley C. Validation of the HIV Treatment Satisfaction Questionnaire (HIVTSQ). Qual Life Res. 2001;10:517\u201331. https:\/\/doi.org\/10.1023\/A:1013050904635.","journal-title":"Qual Life Res"},{"key":"2656_CR14","doi-asserted-by":"publisher","first-page":"239","DOI":"10.2165\/11631340-000000000-00000","volume":"5","author":"C Marant","year":"2012","unstructured":"Marant C, Longin J, Gauchoux R, Arnould B, Spizak C, Marrel A, Patrick DL, Van Ganse E. Long-term treatment acceptance: what is it, and how can it be assessed? Patient. 2012;5:239\u201349. https:\/\/doi.org\/10.2165\/11631340-000000000-00000.","journal-title":"Patient"},{"key":"2656_CR15","unstructured":"U.S. Food and Drug Administration. Guidance for Industry, Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims. 2009. https:\/\/www.fda.gov\/media\/77832\/download. Accessed 24 Jan 2023."},{"key":"2656_CR16","unstructured":"Nunnally J, Bernstein I. Psychometric theory: McGraw-Hill; 1994."},{"key":"2656_CR17","unstructured":"Nunnally J. Psychometric theory: McGraw-Hill; 1978."},{"key":"2656_CR18","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1037\/0033-2909.86.2.420","volume":"86","author":"PE Shrout","year":"1979","unstructured":"Shrout PE, Fleiss JL. Intraclass correlations: uses in assessing rater reliability. Psychol Bull. 1979;86:420\u20138. https:\/\/doi.org\/10.1037\/0033-2909.86.2.420.","journal-title":"Psychol Bull"},{"key":"2656_CR19","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.jcm.2016.02.012","volume":"15","author":"TK Koo","year":"2016","unstructured":"Koo TK, Li MY. A guideline of selecting and reporting intraclass correlation coefficients for reliability research. J Chiropr Med. 2016;15:155\u201363. https:\/\/doi.org\/10.1016\/j.jcm.2016.02.012.","journal-title":"J Chiropr Med"},{"key":"2656_CR20","unstructured":"Fleiss J. The design analysis of clinical experiments Wiley; 1986."},{"key":"2656_CR21","unstructured":"Rosner B. Fundamentals of Biostatistics: Cengage Learning 2015."},{"key":"2656_CR22","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1023\/a:1015291021312","volume":"11","author":"N Aaronson","year":"2002","unstructured":"Aaronson N, Alonso J, Burnam A, Lohr KN, Patrick DL, Perrin E, Stein RE. Assessing health status and quality-of-life instruments: attributes and review criteria. Qual Life Res. 2002;11:193\u2013205. https:\/\/doi.org\/10.1023\/a:1015291021312.","journal-title":"Qual Life Res"},{"key":"2656_CR23","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1177\/009286150203600127","volume":"36","author":"O Olivier Chassany","year":"2002","unstructured":"Olivier Chassany O, Sagnier P, Marquis P, Fullerton S. For the European regulatory issues on quality of life assessment group. Drug Inf J. 2002;36:209\u201338.","journal-title":"Drug Inf J"},{"key":"2656_CR24","volume-title":"Statistical Power Analysis for the Behavioural Sciences","author":"J Cohen","year":"1988","unstructured":"Cohen J. Statistical Power Analysis for the Behavioural Sciences. New York: Routledge; 1988."},{"key":"2656_CR25","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1037\/0033-2909.107.2.238","volume":"107","author":"PM Bentler","year":"1990","unstructured":"Bentler PM. Comparative fit indexes in structural models. Psychol Bull. 1990;107:238\u201346. https:\/\/doi.org\/10.1037\/0033-2909.107.2.238.","journal-title":"Psychol Bull"},{"key":"2656_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/10705519909540118","volume":"6","author":"L Hu","year":"2009","unstructured":"Hu L, Bentler M. Cutoff criteria for fit indexes in covariance structure analysis: Conventional criteria versus new alternatives. Struct Equ Modeling. 2009;6:1\u201355. https:\/\/doi.org\/10.1080\/10705519909540118.","journal-title":"Struct Equ Modeling"},{"key":"2656_CR27","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1177\/0049124192021002005","volume":"21","author":"M Browne","year":"1992","unstructured":"Browne M, Cudeck R. Alternative ways of assessing model fit. Socio Methods Res. 1992;21:230\u201358.","journal-title":"Socio Methods Res"},{"key":"2656_CR28","volume-title":"Statistical power analysis for behavioral sciences","author":"J Cohen","year":"1988","unstructured":"Cohen J. Statistical power analysis for behavioral sciences. 2nd ed. New York, NY: Lawrence Erlbaum Associates; 1988.","edition":"2"},{"key":"2656_CR29","volume-title":"A handbook of test construction: introduction to psychometric design","author":"P Kline","year":"2015","unstructured":"Kline P. A handbook of test construction: introduction to psychometric design. New York, NY: Routledge; 2015."}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-023-02656-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-023-02656-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-023-02656-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,27]],"date-time":"2023-10-27T11:09:16Z","timestamp":1698404956000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-023-02656-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,30]]},"references-count":29,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["2656"],"URL":"https:\/\/doi.org\/10.1007\/s12325-023-02656-1","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,30]]},"assertion":[{"value":"21 June 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 August 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The PIN Questionnaire is a modified version of the VAPI Sanofi Pasteur, 2009 All Rights Reserved. VAPI contact information and permission to use: Mapi Research Trust, Lyon, France. Email: PROinformation@mapi-trust.org\u2014internet: . Dominy Browning and Christina Donatti are employees of ViiV Healthcare and may own stocks\/shares in GSK. Vasiliki Chounta (current affiliation: none) was an employee of ViiV Healthcare at the time of the study and may own stocks\/shares in GSK. Jeremy Lambert (current affiliation: UCB Pharma, Colombes, France), Mickael Henry-Szatkowski (current affiliation: IQVIA, Patient Centered Solution, Paris, France), and Hilary F. Byrnes were employees at the time the study was conducted of ICON plc which was paid to conduct the project.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This post hoc psychometric analysis was conducted on anonymous data and no direct participant contact or primary collection of individual human participant data occurred. Study results are in tabular form and aggregate analyses that omit participant identification, therefore informed consent or ethics committee or IRB approval were not required. The PRO data used in this analysis were a secondary endpoint in two clinical trials: ATLAS and FLAIR, both of which were conducted in accordance with the principles founded in the Declaration of Helsinki and with Good Clinical Practice. The ATLAS and FLAIR protocols were approved by an institutional review board or ethics committee of each study site. All participants provided written informed consent to participate in the clinical trials and any subsequent analysis of the data as it was derived from those clinical trials.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}